vs
ICU MEDICAL INC（ICUI）与PennyMac Financial Services, Inc.（PFSI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是PennyMac Financial Services, Inc.的1.0倍（$540.7M vs $538.0M），PennyMac Financial Services, Inc.净利率更高（1752.5% vs -2.9%，领先1755.4%），PennyMac Financial Services, Inc.同比增速更快（14.4% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-1.7B），过去两年PennyMac Financial Services, Inc.的营收复合增速更高（32.7% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
PennyMac Financial Services是总部位于美国加利福尼亚州西湖村的住宅抵押贷款企业，核心业务涵盖美国抵押贷款的发放、贷后服务，以及抵押贷款市场相关投资管理。公司下设两家子公司，其中PNMAC资本管理有限公司负责运营旗下的抵押贷款不动产投资信托（REIT）PennyMac Mortgage Investment Trust。
ICUI vs PFSI — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $538.0M |
| 净利润 | $-15.7M | $106.8M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 25.0% |
| 净利率 | -2.9% | 1752.5% |
| 营收同比 | -14.1% | 14.4% |
| 净利润同比 | 34.0% | 2.2% |
| 每股收益（稀释后） | $-0.63 | $1.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $540.7M | $538.0M | ||
| Q3 25 | $537.0M | $632.9M | ||
| Q2 25 | $548.9M | $444.7M | ||
| Q1 25 | $604.7M | $430.9M | ||
| Q4 24 | $629.8M | $470.1M | ||
| Q3 24 | $589.1M | $411.8M | ||
| Q2 24 | $596.5M | $406.1M | ||
| Q1 24 | $566.7M | $305.7M |
| Q4 25 | $-15.7M | $106.8M | ||
| Q3 25 | $-3.4M | $181.5M | ||
| Q2 25 | $35.3M | $136.5M | ||
| Q1 25 | $-15.5M | $76.3M | ||
| Q4 24 | $-23.8M | $104.5M | ||
| Q3 24 | $-33.0M | $69.4M | ||
| Q2 24 | $-21.4M | $98.3M | ||
| Q1 24 | $-39.5M | $39.3M |
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
| Q4 25 | 1.0% | 25.0% | ||
| Q3 25 | 2.6% | 37.3% | ||
| Q2 25 | 1.9% | 17.2% | ||
| Q1 25 | 2.1% | 24.2% | ||
| Q4 24 | 6.0% | 27.5% | ||
| Q3 24 | 1.4% | 22.8% | ||
| Q2 24 | 1.3% | 33.0% | ||
| Q1 24 | -1.9% | 14.4% |
| Q4 25 | -2.9% | 1752.5% | ||
| Q3 25 | -0.6% | 28.7% | ||
| Q2 25 | 6.4% | 30.7% | ||
| Q1 25 | -2.6% | 17.7% | ||
| Q4 24 | -3.8% | 2559.8% | ||
| Q3 24 | -5.6% | 16.8% | ||
| Q2 24 | -3.6% | 24.2% | ||
| Q1 24 | -7.0% | 12.9% |
| Q4 25 | $-0.63 | $1.97 | ||
| Q3 25 | $-0.14 | $3.37 | ||
| Q2 25 | $1.43 | $2.54 | ||
| Q1 25 | $-0.63 | $1.42 | ||
| Q4 24 | $-0.97 | $1.95 | ||
| Q3 24 | $-1.35 | $1.30 | ||
| Q2 24 | $-0.88 | $1.85 | ||
| Q1 24 | $-1.63 | $0.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $410.0M |
| 总债务越低越好 | — | $6.2B |
| 股东权益账面价值 | $2.1B | $4.3B |
| 总资产 | $4.1B | $29.4B |
| 负债/权益比越低杠杆越低 | — | 1.45× |
8季度趋势，按日历期对齐
| Q4 25 | — | $410.0M | ||
| Q3 25 | — | $62.2M | ||
| Q2 25 | — | $462.3M | ||
| Q1 25 | — | $443.4M | ||
| Q4 24 | $308.6M | $420.6M | ||
| Q3 24 | $312.5M | $667.9M | ||
| Q2 24 | $302.6M | $188.8M | ||
| Q1 24 | $251.4M | $69.0K |
| Q4 25 | — | $6.2B | ||
| Q3 25 | — | $6.2B | ||
| Q2 25 | — | $5.6B | ||
| Q1 25 | — | $5.8B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | — | $4.9B | ||
| Q2 24 | — | $4.9B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | $2.1B | $4.3B | ||
| Q3 25 | $2.1B | $4.2B | ||
| Q2 25 | $2.1B | $4.0B | ||
| Q1 25 | $2.0B | $3.9B | ||
| Q4 24 | $2.0B | $3.8B | ||
| Q3 24 | $2.0B | $3.7B | ||
| Q2 24 | $2.0B | $3.7B | ||
| Q1 24 | $2.1B | $3.6B |
| Q4 25 | $4.1B | $29.4B | ||
| Q3 25 | $4.1B | $25.4B | ||
| Q2 25 | $4.1B | $24.2B | ||
| Q1 25 | $4.2B | $23.9B | ||
| Q4 24 | $4.2B | $26.1B | ||
| Q3 24 | $4.3B | $22.9B | ||
| Q2 24 | $4.3B | $21.6B | ||
| Q1 24 | $4.3B | $19.8B |
| Q4 25 | — | 1.45× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 1.38× | ||
| Q1 25 | — | 1.48× | ||
| Q4 24 | — | 1.37× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.35× | ||
| Q1 24 | — | 1.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $-1.7B |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-1.7B |
| 自由现金流率自由现金流/营收 | 6.6% | -309.3% |
| 资本支出强度资本支出/营收 | 4.6% | 2.2% |
| 现金转化率经营现金流/净利润 | — | -15.46× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $-1.4B |
8季度趋势，按日历期对齐
| Q4 25 | $60.6M | $-1.7B | ||
| Q3 25 | $56.7M | $-697.4M | ||
| Q2 25 | $11.2M | $-131.3M | ||
| Q1 25 | $51.3M | $1.1B | ||
| Q4 24 | $40.2M | $-4.5B | ||
| Q3 24 | $36.1M | $-393.7M | ||
| Q2 24 | $82.0M | $-1.1B | ||
| Q1 24 | $45.8M | $-897.9M |
| Q4 25 | $36.0M | $-1.7B | ||
| Q3 25 | $27.6M | $-699.4M | ||
| Q2 25 | $-8.5M | $-132.6M | ||
| Q1 25 | $36.7M | $1.1B | ||
| Q4 24 | $16.1M | $-4.5B | ||
| Q3 24 | $16.2M | $-393.9M | ||
| Q2 24 | $62.5M | $-1.1B | ||
| Q1 24 | $29.9M | $-898.9M |
| Q4 25 | 6.6% | -309.3% | ||
| Q3 25 | 5.1% | -110.5% | ||
| Q2 25 | -1.5% | -29.8% | ||
| Q1 25 | 6.1% | 247.3% | ||
| Q4 24 | 2.6% | -964.7% | ||
| Q3 24 | 2.7% | -95.6% | ||
| Q2 24 | 10.5% | -269.2% | ||
| Q1 24 | 5.3% | -294.1% |
| Q4 25 | 4.6% | 2.2% | ||
| Q3 25 | 5.4% | 0.3% | ||
| Q2 25 | 3.6% | 0.3% | ||
| Q1 25 | 2.4% | 0.1% | ||
| Q4 24 | 3.8% | 0.4% | ||
| Q3 24 | 3.4% | 0.0% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 2.8% | 0.3% |
| Q4 25 | — | -15.46× | ||
| Q3 25 | — | -3.84× | ||
| Q2 25 | 0.32× | -0.96× | ||
| Q1 25 | — | 13.97× | ||
| Q4 24 | — | -43.39× | ||
| Q3 24 | — | -5.68× | ||
| Q2 24 | — | -11.12× | ||
| Q1 24 | — | -22.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PFSI
暂无分部数据
